Literature DB >> 29229274

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

L D'Ambrosio1, G Bothamley2, J A Caminero Luna3, R Duarte4, L Guglielmetti5, M Muñoz Torrico6, M C Payen7, N Saavedra Herrera8, M A Salazar Lezama6, A Skrahina9, M Tadolini10, S Tiberi11, N Veziris12, G B Migliori13.   

Abstract

As recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known as 'TB Consilium'. This body usually includes different medical specialities, competences and perspectives (e.g., clinical expertise both for adults and children; surgical, radiological and public health expertise; psychological background and nursing experience, among others), thus lowering the risk of making mistakes - or managing the patients inappropriately, in order to improve their clinical outcomes. At present, several high MDR-TB burden countries in the different WHO regions (and beyond) have introduced TB Consilium-like bodies at the national or subnational level to reach consensus on the best treatment approach for their patients affected by TB. In addition, in countries/settings where a formal system of consultation does not exist, specialized staff from MDR-TB reference centres or international organizations usually spend a considerable amount of their working time responding to phone or e-mail clinical queries on how to manage M/XDR-TB cases. The aim of this manuscript is to describe the different experiences with the TB Consilia both at the international level (European Respiratory Society - ERS/WHO TB Consilium) and in some of the countries where this experience operates successfully in Europe and beyond. The Consilium experiences are described around the following topics: (1) history, aims and focus; (2) management and funding; (3) technical functioning and structure; (4) results achieved. In addition a comparative analysis of the TB Consilia in the different countries has been performed.
Copyright © 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Clinical management; Consilium; Drug resistance; MDR-TB; Prevention; XDR-TB

Mesh:

Year:  2017        PMID: 29229274     DOI: 10.1016/j.rppnen.2017.10.005

Source DB:  PubMed          Journal:  Pulmonology        ISSN: 2531-0429


  6 in total

Review 1.  Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.

Authors:  Simon Tiberi; Marcela Muñoz Torrico; Ananna Rahman; Maria Krutikov; Dina Visca; Denise Rossato Silva; Heinke Kunst; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

2.  International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis.

Authors:  Giovanni Battista Migliori; Rosella Centis; Lia D'Ambrosio; Denise Rossato Silva; Adrian Rendon
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

3.  Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021.

Authors:  G B Migliori; S Tiberi; A L García-Basteiro; R Duarte
Journal:  Pulmonology       Date:  2020-11-17

4.  Investigating the response to COVID-19 and understanding severe TB cases: The 2022 Pulmonology TB series.

Authors:  G B Migliori; S Tiberi; R Duarte
Journal:  Pulmonology       Date:  2022-02-08

5.  Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.

Authors:  Yousra Kherabi; Mathilde Fréchet-Jachym; Christophe Rioux; Yazdan Yazdanpanah; Frédéric Méchaï; Valérie Pourcher; Jérôme Robert; Lorenzo Guglielmetti
Journal:  Emerg Infect Dis       Date:  2022-09       Impact factor: 16.126

6.  Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda.

Authors:  Joseph Baruch Baluku; Richard Katuramu; Joshua Naloka; Enock Kizito; Martin Nabwana; Felix Bongomin
Journal:  BMC Pulm Med       Date:  2021-07-10       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.